|

surufatinib + camrelizumab + nab-paclitaxel + S-1 Clinical Trials

1 actively recruiting trial

Pipeline

Phase 1/2: 1

Top Sponsors

  • Chinese PLA General Hospital1

Indications

  • PDAC - Pancreatic Ductal Adenocarcinoma1
  • Pancreatic Neoplasms1
  • Pancreas Cancer1
  • Pancreatic Cancer1
  • Cancer1

Other1 trial

Surufatinib Plus Camrelizumab and AS in First Line Treatment of Advanced Metastatic Pancreatic Cancer
Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.